Share Twitter LinkedIn Facebook Email Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study, investigating belantamab versus pomalidomide and dexamethasone.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read